ZKSCAN5 Inhibitors
ZKSCAN5 inhibitors include a variety of chemical compounds that influence the protein's function by acting on different cellular pathways. For instance, JQ1, a bromodomain inhibitor, can impede ZKSCAN5 by modifying chromatin accessibility and structure, thus inhibiting ZKSCAN5's target gene activation. Similarly, CX-4945, a CK2 kinase inhibitor, may reduce ZKSCAN5's functional activity by affecting its phosphorylation state and subsequent DNA-binding affinity. Another compound, 5-Azacytidine, inhibits DNA methyltransferases, leading to DNA hypomethylation that could alter ZKSCAN5's DNA-binding profile. Proteasome inhibitors such as MG132 and Bortezomib could affect ZKSCAN5 indirectly by stabilizing regulatory proteins that control ZKSCAN5's stability and subcellular localization, while histone deacetylase inhibitors like Trichostatin A and Sodium Butyrate change chromatin structure, potentiallyimpacting ZKSCAN5's ability to bind DNA effectively.
Furthermore, PD98059 and LY294002 target the MAPK/ERK and PI3K/AKT signaling pathways, respectively, which may indirectly inhibit ZKSCAN5's activity if it is regulated downstream of these pathways. Rapamycin's inhibition of mTOR signaling could lead to a broader alteration in cellular growth conditions, thus affecting ZKSCAN5's activity. Thalidomide, known for inducing the degradation of several zinc finger proteins, might also decrease ZKSCAN5's stability and activity. Alsterpaullone, as a cyclin-dependent kinase inhibitor, could disrupt cell cycle-related functions of ZKSCAN5 by halting cell cycle progression. Across these diverse mechanisms, each chemical compound contributes to the inhibition of ZKSCAN5 by targeting specific signaling or regulatory pathways, thus preventing the protein from executing its role in gene regulation and other cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 is a bromodomain inhibitor that binds to the BET family of proteins, displacing them from chromatin and therefore reducing transcriptional activation of certain genes. As ZKSCAN5 can bind to gene promoters, JQ1 could reduce ZKSCAN5's ability to activate its target genes by altering the chromatin structure and accessibility. | ||||||
CX-4945 | 1009820-21-6 | sc-364475 sc-364475A | 2 mg 50 mg | $183.00 $800.00 | 9 | |
CX-4945 is a specific inhibitor of protein kinase CK2. Since CK2 phosphorylation can influence the DNA-binding affinity of zinc finger proteins, inhibiting CK2 could decrease the functional activity of ZKSCAN5 by affecting its phosphorylation state and DNA-binding capacity. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor. Hypomethylation of DNA could alter the binding affinity of ZKSCAN5 to its target DNA sequences, potentially inhibiting its ability to regulate gene expression. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor. By preventing the degradation of regulatory proteins that may control the stability and localization of ZKSCAN5, MG132 could indirectly affect the functional activity of ZKSCAN5 within the cell. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. Altered histone acetylation can change the chromatin structure, potentially affecting the ability of ZKSCAN5 to access and bind to its DNA targets within the nucleus. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that can prevent the activation of the MAPK/ERK pathway. If ZKSCAN5 is involved in gene regulation pathways that are downstream of MAPK/ERK signaling, its activity could be indirectly inhibited by PD98059 through these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that could downregulate AKT signaling, a pathway that might influence the nuclear localization and transcriptional activity of ZKSCAN5. By inhibiting this pathway, LY294002 could indirectly reduce the activity of ZKSCAN5. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. Since mTOR signaling can affect protein synthesis and cellular growth processes, inhibiting mTOR with rapamycin could indirectly inhibit ZKSCAN5 by altering the cellular context in which it operates. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide, through its cereblon-binding, has been shown to induce the degradation of several zinc finger proteins. It may potentially lead to the decreased stability and activity of ZKSCAN5 by promoting its degradation. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor and can interfere with cell cycle progression. As ZKSCAN5 may have roles in cell cycle regulation, inhibiting these kinases could reduce ZKSCAN5 activity indirectly by affecting the cell cycle. | ||||||